Analysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $52.33

Shares of Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) have been assigned an average rating of "Hold" from the six brokerages that are presently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $52.33.

A number of research firms have commented on OMCL. Barclays lifted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an "equal weight" rating in a report on Thursday, October 31st. Benchmark reaffirmed a "buy" rating and set a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com cut shares of Omnicell from a "buy" rating to a "hold" rating in a report on Tuesday, December 10th. Bank of America lowered their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating for the company in a report on Monday, January 6th. Finally, JPMorgan Chase & Co. raised their price target on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a report on Thursday, November 21st.

Insider Transactions at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now owns 58,427 shares of the company's stock, valued at $2,763,597.10. The trade was a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.64% of the company's stock.

Hedge Funds Weigh In On Omnicell

Institutional investors and hedge funds have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Omnicell by 51.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company's stock valued at $35,000 after acquiring an additional 273 shares in the last quarter. Johnson Financial Group Inc. bought a new position in Omnicell during the 4th quarter valued at $37,000. Van ECK Associates Corp increased its position in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after purchasing an additional 315 shares during the period. Headlands Technologies LLC bought a new stake in shares of Omnicell in the 4th quarter worth $53,000. Finally, First Horizon Advisors Inc. lifted its holdings in shares of Omnicell by 36.3% in the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock valued at $59,000 after buying an additional 355 shares during the period. Institutional investors own 97.70% of the company's stock.

Omnicell Stock Up 0.4 %

Shares of Omnicell stock traded up $0.15 during trading on Monday, reaching $40.12. The company had a trading volume of 470,060 shares, compared to its average volume of 406,914. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The firm's fifty day moving average is $43.21 and its 200-day moving average is $43.87. The company has a market cap of $1.86 billion, a price-to-earnings ratio of 148.60, a price-to-earnings-growth ratio of 7.52 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, analysts anticipate that Omnicell will post 1.09 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.